INNOVIVA, INC. Effective Income Tax Rate Reconciliation, Other Adjustments, Amount
INNOVIVA, INC. (INVA) reported Effective Income Tax Rate Reconciliation, Other Adjustments, Amount of -$488.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationOtherAdjustments · last filed 2026-02-25
- INNOVIVA, INC. effective income tax rate reconciliation, other adjustments, amount for fiscal 2025 was -$488.00K.
- INNOVIVA, INC. effective income tax rate reconciliation, other adjustments, amount for fiscal 2024 was -$2.24M, a 284.00% decline from fiscal 2023.
- INNOVIVA, INC. effective income tax rate reconciliation, other adjustments, amount for fiscal 2023 was $1.22M.
- INNOVIVA, INC. effective income tax rate reconciliation, other adjustments, amount for fiscal 2022 was -$125.00K, a 111.07% decline from fiscal 2021.
| Period end | Effective Income Tax Rate Reconciliation, Other Adjustments, Amount 12 month |
|---|---|
| 2025-12-31 | -$488.00K 10-K · filed 2026-02-25 |
| 2024-12-31 | -$2.24M 10-K · filed 2026-02-25 |
| 2023-12-31 | $1.22M 10-K · filed 2026-02-25 |
| 2022-12-31 | -$125.00K 10-K · filed 2025-02-26 |
| 2021-12-31 | $1.13M 10-K/A · filed 2024-03-05 |
| 2020-12-31 | $839.00K 10-K · filed 2023-02-28 |
| 2019-12-31 | $326.00K 10-K/A · filed 2022-03-17 |
| 2018-12-31 | $310.00K 10-K · filed 2021-02-25 |
| 2017-12-31 | -$1.51M 10-K · filed 2020-02-19 |
| 2016-12-31 | -$122.00K 10-K · filed 2019-02-19 |
| 2015-12-31 | $170.00K 10-K · filed 2018-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |